133 related articles for article (PubMed ID: 22872740)
1. Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate.
Boswell CA; Mundo EE; Zhang C; Stainton SL; Yu SF; Lacap JA; Mao W; Kozak KR; Fourie A; Polakis P; Khawli LA; Lin K
J Nucl Med; 2012 Sep; 53(9):1454-61. PubMed ID: 22872740
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer.
Boswell CA; Yadav DB; Mundo EE; Yu SF; Lacap JA; Fourie-O'Donohue A; Kozak KR; Ferl GZ; Zhang C; Ho J; Ulufatu S; Khawli LA; Lin K
Oncotarget; 2019 Oct; 10(58):6234-6244. PubMed ID: 31692898
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
4. An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.
Boswell CA; Mundo EE; Firestein R; Zhang C; Mao W; Gill H; Young C; Ljumanovic N; Stainton S; Ulufatu S; Fourie A; Kozak KR; Fuji R; Polakis P; Khawli LA; Lin K
Br J Pharmacol; 2013 Jan; 168(2):445-57. PubMed ID: 22889168
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1.
Williams SP; Ogasawara A; Tinianow JN; Flores JE; Kan D; Lau J; Go M; Vanderbilt AN; Gill HS; Miao L; Goldsmith J; Rubinfeld B; Mao W; Firestein R; Yu SF; Marik J; Terwisscha van Scheltinga AG
Oncotarget; 2016 May; 7(18):25103-12. PubMed ID: 27029064
[TBL] [Abstract][Full Text] [Related]
6. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
[TBL] [Abstract][Full Text] [Related]
7. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
Buchsbaum DJ; Wahl RL; Glenn SD; Normolle DP; Kaminski MS
Cancer Res; 1992 Feb; 52(3):637-42. PubMed ID: 1732052
[TBL] [Abstract][Full Text] [Related]
8. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
9. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
10. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.
Afar DE; Bhaskar V; Ibsen E; Breinberg D; Henshall SM; Kench JG; Drobnjak M; Powers R; Wong M; Evangelista F; O'Hara C; Powers D; DuBridge RB; Caras I; Winter R; Anderson T; Solvason N; Stricker PD; Cordon-Cardo C; Scher HI; Grygiel JJ; Sutherland RL; Murray R; Ramakrishnan V; Law DA
Mol Cancer Ther; 2004 Aug; 3(8):921-32. PubMed ID: 15299075
[TBL] [Abstract][Full Text] [Related]
11. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
[TBL] [Abstract][Full Text] [Related]
14. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
15. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF.
Hall MA; Pinkston KL; Wilganowski N; Robinson H; Ghosh P; Azhdarinia A; Vazquez-Arreguin K; Kolonin AM; Harvey BR; Sevick-Muraca EM
J Nucl Med; 2012 Sep; 53(9):1427-37. PubMed ID: 22872743
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
17. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
Chang HP; Li Z; Shah DK
Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
[TBL] [Abstract][Full Text] [Related]
18. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
19. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
20. Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals.
Datta-Mannan A; Choi H; Jin Z; Liu L; Lu J; Stokell DJ; Murphy AT; Dunn KW; Martinez MM; Feng Y
PLoS One; 2024; 19(4):e0293703. PubMed ID: 38630694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
